ASCO 2023

June 02-06, 2023
Chicago, IL

American Society of Clinical Oncology 2023

Explore more Oncology congress materials

Results(1)

Hematology-Oncology

Results from the Pivotal Phase 2b HERIZON-BTC-01 Study: Zanidatamab in Previously-treated HER2-amplified Biliary Tract Cancer (BTC)

Author(s): Shubham Pant, MD Anderson Cancer Center, et al.

Disclaimer

This AI model is continuing to learn and its responses are based on learned data patterns. It should not replace professional judgment. Please verify the information before use, and feedback is welcome to improve its accuracy.

Please do not include personal or confidential information in your searches. For information on how to report an adverse event or product complaint for a Jazz product, please visit: https://www.jazzpharma.com/medicines/drug-safety/.